Dermatology Inovalon Clearinghouse Integration for Prior Authorization Automation

Klivira provides robust integration with Inovalon Clearinghouse, specifically tailored to automate prior authorizations for high-volume dermatology services and medications. This ensures efficient, accurate submission and tracking for clinics and health systems.

Revenue cycle leaders and PA coordinators in dermatology face unique challenges, from managing complex biologic step therapy requirements to navigating payer policies for Mohs surgery. Integrating with a clearinghouse like Inovalon is crucial for claims submission and analytics, but prior authorization workflows often remain manual. Klivira bridges this gap, automating the PA process and optimizing data flow through your existing clearinghouse channels.

The Intersection of Dermatology PA and Inovalon Clearinghouse Operations

Dermatology practices frequently encounter prior authorization requirements for high-cost biologics, specialty topicals, and specific procedures like Mohs micrographic surgery. Efficiently managing these PAs and transmitting associated claims data through a clearinghouse like Inovalon is critical for revenue integrity and quality reporting. Klivira streamlines the PA initiation and submission process, ensuring that the necessary clinical documentation is prepared for electronic transmission via channels such as X12 278.

Key Dermatology PA Triggers Handled via Inovalon Clearinghouse

Biologics for psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi, Humira, Enbrel)
Biologics for atopic dermatitis (e.g., Dupixent, Adbry, Ebglyss)
Biologics for hidradenitis suppurativa (e.g., Humira, Cosentyx)
Mohs micrographic surgery (especially for cosmetically sensitive areas)
Advanced skin cancer treatments (e.g., Keytruda, Opdiva, Yervoy)
Phototherapy, particularly for home-based units

Optimizing Prior Authorization Submission through Inovalon

Klivira's platform automates the generation and submission of prior authorization requests, integrating directly with your EMR and connecting to clearinghouses like Inovalon. This integration ensures that detailed clinical documentation, such as PASI/BSA scores for psoriasis or AAD Appropriate Use Criteria for Mohs surgery, is accurately captured and transmitted. By leveraging electronic prior authorization (ePA) standards, Klivira reduces manual intervention and accelerates the PA lifecycle for dermatology-specific treatments.

Critical Documentation for Dermatology PA Success

Disease severity scores (PASI, BSA, EASI, SCORAD) and diagnosis criteria
Documentation of prior topical, phototherapy, or conventional systemic therapy trials
Pre-biologic screenings (e.g., TB, hepatitis) and step therapy compliance
Mohs surgery site, tumor type, and adherence to AAD Appropriate Use Criteria
NCCN guidelines for advanced skin cancer treatments

Addressing Common Dermatology PA Denials with Klivira and Inovalon

Common dermatology PA denials, such as insufficient documentation of step therapy for biologics or Mohs AUC mismatches, can significantly impact revenue. Klivira's intelligent automation engine is designed with AAD guideline-aware logic to proactively identify and flag missing documentation. When integrated with Inovalon, this ensures that submissions are complete and accurate from the outset, reducing denial rates and facilitating quicker payer responses and comprehensive data for analytics.

Klivira's Approach to Dermatology-Specific Workflows

Beyond initial PA submission, Klivira supports dermatology's unique workflow constraints, including periodic re-authorization for chronic biologic treatments and accurate routing for medical versus pharmacy benefit claims. Our platform's ability to manage these nuances, combined with seamless data flow through Inovalon Clearinghouse, empowers dermatology practices to maintain continuity of care and optimize their revenue cycle for complex cases.

Frequently asked questions

How does Klivira handle specific dermatology biologics requiring PA through Inovalon?

Klivira's platform incorporates AAD guideline-aware logic to manage step therapy requirements for biologics like Dupixent, Cosentyx, and Tremfya. It automates the collection of necessary clinical data from your EMR and formats it for electronic submission via X12 278 to Inovalon Clearinghouse, ensuring all payer-specific criteria are met.

What EMR touchpoints are integrated for dermatology PA submissions to Inovalon?

Klivira integrates directly with your EMR via SMART on FHIR or other standard APIs. This allows for seamless extraction of patient demographics, diagnoses, medication history, and clinical notes relevant to dermatology PA, which are then prepared for transmission through Inovalon Clearinghouse.

Can Klivira assist with re-authorizations for chronic dermatology conditions?

Yes, Klivira is designed to manage the lifecycle of prior authorizations, including periodic re-authorizations for chronic biologic treatments common in dermatology. The platform tracks authorization expiry dates and proactively initiates the re-authorization process, minimizing lapses in coverage and ensuring continuity of care.

How does Klivira ensure compliance with AAD/NCCN guidelines in submissions?

Klivira's automation engine is configured with rulesets derived from clinical guidelines like those from the AAD for psoriasis and atopic dermatitis, and NCCN for skin cancers. This ensures that submitted documentation aligns with appropriate use criteria and payer medical policies, reducing the likelihood of denials related to clinical non-compliance.

What is the role of X12 278 in dermatology PA submissions via Inovalon?

X12 278 is the standardized electronic transaction for healthcare services prior authorization requests. Klivira generates and manages the necessary data for these transactions, facilitating efficient and compliant electronic submission of dermatology prior authorizations through Inovalon Clearinghouse to various payers, accelerating the review process.